Partners to advance personalised treatments for long Covid

""

PrecisionLife and the Metrodora Institute have agreed a partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases.

The diseases include long Covid, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), amyotrophic lateral sclerosis (ALS), Sjögren’s syndrome, and many more.

The partners will first develop and validate genotypic diagnostics that provide clinicians with an accurate view of a patient’s risk of disease; then, using the molecular profile of their underlying disease mechanisms, report back effective prescribing decisions and drug discovery opportunities to improve patient outcomes.

The first products developed will be in long Covid and ME/CFS, building on PrecisionLife’s existing studies.

“We’ve gone far too long without providing clinicians and patients with an informative readout of the biological drivers associated with these conditions. Moving with unprecedented speed and scale, we will work to rapidly establish this new class of genotypic diagnostic tools paired with targeted clinical trials at Metrodora,” said Rohit Gupta, Metrodora’s Chief Scientific Officer.

The collaboration will extend to the identification and clinical validation of safe and effective drug repurposing candidates associated with disease modifying mechanisms and accelerate the approval of effective new personalised treatments for patients.

“In Metrodora we have a partner that is focused on the diagnosis and treatment of some of the most challenging and intractable diseases,” said Steve Gardner, PrecisionLife’s CEO. “With our combined disease insights, patient support and clinical expertise, we’re building a powerful engine that will transform the rate at which both new diagnostics and effective therapies can be clinically validated and provided to patient communities that are massively underserved – improving health for millions of people.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free